Abstract:To study the clinical characteristics, risk factors and therapeutic outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia (Ph(+)aALL).The clinical data of 117 newly diagnosed adults with Ph(+)ALL in our hospital between January 1995 and December 2009 were retrospectively analyzed. And their prognoses were followed up.There were 117(16.1%) of 727 aALL patients diagnosed as Ph(+)aALL. Among the 117 cases, 64.1% patients were classified as pre-B immunophenotype and 31.3% as common B immunophenotype, 37.5% patients with co-expression of myeloid antigens (CD13 or CD33), and 98.4% patients with positive CD34. The complete remission (CR) rate after 1 or 2 cycles of induction chemotherapy was 62.2% in Ph(+)aALL group versus 82% in Ph(-)aALL group (P = 0.000). The median disease-free survival time of Ph(+) group was 6 months and the median survival time was 9 months. Sole karyotype abnormality subgroup t(9;22) accounted for 53% of all Ph(+)aALL patients and additional karyotype abnormality subgroup, t(9;22) plus other chromosome variation, accounted for 47%. Patients in sole karyotype abnormality subgroup had slightly lower CR rate (59.6% vs 62.5%, P = 0.768), longer median survival time (7 months vs 4 months, P = 0.158), and higher 3-year overall survival rate (27.3% vs 14.4%, P = 0.271). For the myeloid antigen co-expressed patients and the only lymphocytic antigen expressed ones, CR rate was 56.0% and 61.5% (P = 0.750), the median survival time was 5 months and 4 months (P = 0.182), and the 3-year overall survival rate was 16.0% and 15.0% (P = 0.354), respectively. In the imatinib plus combination chemotherapy treatment group, 81.3% patients achieved CR, compared with that of 58.3% in patients treated with only traditional combination chemotherapy (P = 0.083). The median survival time was 9.5 months and 6 months (P = 0.003) in these two subgroup, and 3-year overall survival rate was 52.2% and 10.3% (P = 0.029), respectively. For the patients receiving allo-HSCT after CR and that receiving traditional consolidation chemotherapy, the median survival time was 15 months and 6 months (P = 0.000), and the 3-year overall survival rate was 62.0% and 10.3% (P = 0.000), respectively. For the patients receiving imatinib as consolidation-maintenance treatment and that receiving allo-HSCT, the median survival time was 12 months and 15 months (P = 0.300), and the 3-year overall survival rate was 64.7% and 62% (P = 0.505), respectively.Of all adult ALL patients, the Ph(+) subgroup accounted for about 16.1%, which have unfavorable prognosis such as lower CR rate and shorter survival duration under traditional chemotherapy. Neither additional chromosome abnormalities to t(9;22) nor co-expression of myeloid antigen had negative effect on CR rate and survival duration. Addition of imatinib to the therapy was beneficial to improve the CR rate and survival duration. Either receiving imatinib as consolidation-maintenance treatment or allo-HSCT after complete remission can improve long-term survival rate of Ph(+) adult ALL group significantly.

[Clinical Characteristics of Children with B Cell Type Acute Lymphoblastic Leukemia Carrying Different Fusion Gene].

Clinical study of Philadelphia chromosome-positive adult acute lymphoblastic leukemia]

Clinical Features and Implications of Childhood Acute Lymphoblastic Leukemia with E2A/PBX1 Fusion Gene

Clinical Features and Prognostic Impact of TCF3–PBX1 in Childhood Acute Lymphoblastic Leukemia: A Single-Center Retrospective Study of 837 Patients from China

Fusion Genes in Childhood Acute Lymphoblastic Leukemia and Its Clinical Significance

Comparative Study on Clinical Features Between TEL-AML1 Positive and Negative Childhood Acute Lymphoblastic Leukemia

[Study on Immunophenotypes and Gene of Acute Lymphoblastic Leukemia]

Clinical Features and Prognostic Significance of Tcf3-Pbx1 Fusion Gene in Chinese Children with Acute Lymphoblastic Leukemia by Using A Modified All-Bfm-95 Protocol

Clinical features and prognosis analysis of children with lymphoid-associated and myeloid-associated antigen positive acute leukemia:a report from the AL-XH-99

Clinical analysis of childhood acute lymphoblastic leukemia with MLL gene rearrangement

[Long-Term Clinical Effect of the CCLG-ALL2008 Regimen in Treatment of Childhood Acute Lymphoblastic Leukemia with Different Molecular Biological Features].

[Clinical analysis of 7 cases of acute B cell lymphoblastic leukemia with t (17;19) (q21-22;p13)/TCF3-HLF fusion]

Analysis of Immunophenotype of Acute Lymphoblastic Leukemia and Clinical Presentations and Prognosis in Children

[Clinical Characteristics and Prognostic Analysis of Children and Adolescents over 10 Years of Age with Acute Lymphoblastic Leukemia].

[Genetic characteristics and its prognostic significance for 217 adult patients with acute lymphoblastic leukemia].

Clinical Characteristics and Prognostic Analysis of Pediatric Pro-B Cell Acute Lymphoblastic Leukemia

Immunophenotypic Features of Bcr/abl Fusion Transcript-Positive B-Lineage Acute Lymphoblast Leukemia

Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia.

Clinical Features and Outcomes of Fusion Gene Defined Adult Ph-negative B-cell Precursor Acute Lymphoblastic Leukemia Patients: A Single Institutional Report.

Cytogenetic and Molecular Features of 1331 Chinese Patients with Primary Acute Lymphoblastic Leukemia (ALL).

Effect of chemotherapy regimen CCLG-ALL-2008 on children with TEL/AML1 fusion gene positive of acute lymphoblastic leukemia